B7-33 10 MG

Dragon Pharma B7-33 10 mg – Selective RXFP1 Agonist for Anti-Fibrotic Research

Dragon Pharma B7-33 10 mg is a synthetic, single-chain peptide derived from the B-chain of human relaxin-2 (H2 relaxin). This peptide acts as a functionally selective agonist for the relaxin family peptide receptor 1 (RXFP1), representing a targeted tool for research into fibrosis, cardiovascular function, and tissue remodeling.

Each vial contains 10 mg of lyophilized B7-33 in a 2 mL format, requiring reconstitution with bacteriostatic water before use. B7-33 has been developed as a more stable and selective alternative to full-length relaxin-2, offering researchers a refined compound for preclinical investigations. For related research compounds, explore our peptides category and specifically SS-31 50 mg for mitochondrial function studies.

What Makes B7-33 Valuable in Research?

B7-33 retains the key structural elements responsible for RXFP1 activation while eliminating domains that may contribute to off-target effects or rapid clearance. Its functionally selective profile allows researchers to investigate RXFP1-mediated signaling pathways with improved specificity compared to native relaxin-2.

The peptide has demonstrated promising preclinical potential in models of tissue fibrosis, cardiac remodeling, and wound healing. By activating RXFP1, B7-33 triggers downstream signaling cascades involving cAMP, MAPK, and PI3K pathways, which are linked to anti-fibrotic, anti-inflammatory, and vasoprotective effects. For researchers investigating peptide-based interventions, TB 500 offers complementary insights into tissue repair mechanisms.

Current research surrounding B7-33 is available through the PubMed database, where investigators can access peer-reviewed studies on its pharmacokinetics and preclinical applications.

Key Research Applications for Dragon Pharma B7-33

• ✔ Investigation of RXFP1-mediated anti-fibrotic mechanisms
• ✔ Cardioprotection and cardiac remodeling studies
• ✔ Wound healing and tissue regeneration research
• ✔ Evaluation of relaxin-2 signaling pathways
• ✔ Preclinical models of fibrotic diseases

Product Details

Dosage & Usage Guidelines

Reconstitution Protocol

• ✔ Use sterile bacteriostatic water for injection
• ✔ Add appropriate volume to achieve desired concentration
• ✔ Swirl gently to dissolve – do not shake vigorously
• ✔ Store reconstituted solution at 2–8°C

Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 10 mg format allows for flexible dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.

Typical Research Parameters

In research settings, B7-33 is typically administered via subcutaneous or intraperitoneal injection. Dosing schedules and concentrations vary widely depending on the experimental design, animal model, and specific research objectives.

• ✔ Commonly used in studies evaluating anti-fibrotic effects
• ✔ Often combined with cardiac function assessment protocols
• ✔ Used to investigate RXFP1-mediated signaling pathways
• ✔ Research models include wound healing and tissue repair

Factors to Consider in Research Protocols

• Functionally selective agonist requires careful dose-response characterization
• Reconstitution stability is limited; prepare fresh solutions for each use
• Individual variation in response may be observed across subjects
• Storage conditions significantly impact peptide stability

Lab Testing & Batch Transparency

Lab status

COA pending release

Third-party analytical testing (COA) for Dragon Pharma B7-33 10 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.

Testing Status

Pending

COA Availability

Not yet published

Batch Verification

In progress

Update

Coming soon

Transparency note: Dragon Pharma publishes batch-specific lab reports once analytical testing is completed and verified.

Awaiting COA

Shipping & Product Authenticity

What to Expect

• ✔ Orders are processed after payment confirmation
• ✔ USA Domestic shipping is typically faster when local stock is selected
• ✔ International orders include tracking, though update frequency may vary by destination
• ✔ Multiple warehouses may result in separate shipments when applicable

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions